[Federal Register Volume 70, Number 121 (Friday, June 24, 2005)]
[Notices]
[Page 36644]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-12497]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Public Notice

AGENCY: Centers for Disease Control and Prevention (CDC), Health and 
Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), National 
Center for Infectious Disease (NCID), Division of Bacterial and Mycotic 
Diseases (DBMD) through its component Branches has lead technical 
responsibility for a number of Category A, B and C bioterrorism agents 
and their associated toxins (Bacillus anthracis, Clostridium botulinum, 
Brucella sps., Burkholderia sps., Staphylococcus entertoxin B, other 
food-or waterborne bacterial pathogens, and other bacterial agents). 
DBMD provides technical support for the Nation's prevention and control 
efforts for human anthrax disease. Since 2001, DBMD has been collecting 
anthrax immune plasma from Department of Defense volunteers who 
received the licensed Anthrax Vaccine Adsorbed (AVA) according to the 
licensed schedule. DBMD has contracted with industry to produce anthrax 
immune globulin (AIG) from the collected anthrax immune plasma using 
anion-exchange chromatography. Since 2003, DBMD has been evaluating the 
efficacy and pharmacokinetics of AIG in small animals. Preliminary 
results of these studies are now available, and are being released to 
the public domain to facilitate development of immunotherapeutic agents 
for treatment of human inhalational anthrax disease. DBMD will continue 
to conduct AIG studies in animals, and will release data to the public 
as soon as the results become available.
    Persons or organizations who are interested in receiving the 
preliminary animal AIG study results, and in receiving future updates, 
should contact CDC and provide a mailing address.
    CDC prefers to receive requests for data electronically. These 
requests can be e-mailed to the attention of Michael J. Detmer at 
[email protected]. Mailed responses can be sent to the following address: 
Michael J. Detmer, Division of Bacterial and Mycotic Diseases, National 
Center for Infectious Diseases, Centers for Disease Control and 
Prevention, 1600 Clifton Rd., NE., Mail Stop C-09, Atlanta, GA 30333.

FOR FURTHER INFORMATION CONTACT: Technical: Clare A. Dykewicz, M.D., 
M.P.H. Division of Bacterial and Mycotic Diseases, National Center for 
Infectious Diseases, Centers for Disease Control and Prevention (CDC), 
1600 Clifton Rd. NE., Mail Stop C 09, Atlanta, GA 30333. Telephone 
(404) 639-4138, e-mail: [email protected].

    Dated: June 13, 2005.
James D. Seligman,
Associate Director for Program Services, Centers for Disease Control 
and Prevention.
[FR Doc. 05-12497 Filed 6-23-05; 8:45 am]
BILLING CODE 4163-18-P